Pacer Advisors
FATE icon

Pacer Advisors’s Fate Therapeutics FATE Stock Holding History

Pacer Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,426
Closed -$4.68K – 2608
2024
Q2 		$4.68K Sell
1,426
-1,968
-58% -$8.62K ﹤0.01% 3642
2024
Q1 		$24.9K Buy
+3,394
New +$21K ﹤0.01% 3399
2021
Q2 		– Sell
-822
Closed -$68K – 1455
2021
Q1 		$68K Sell
822
-576
-41% -$55.2K ﹤0.01% 1387
2020
Q4 		$127K Sell
1,398
-2,020
-59% -$125K ﹤0.01% 1323
2020
Q3 		$137K Buy
+3,418
New +$119K ﹤0.01% 1221
2018
Q4 		– Sell
-4,378
Closed -$71K – 720
2018
Q3 		$71K Buy
+4,378
New +$51.8K ﹤0.01% 1124

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Pacer Advisors's FATE Position: Q3 2024 in Review

Pacer Advisors sold out of Fate Therapeutics (FATE) in Q3 2024, closing a stake of 1,426 shares — an estimated $4.68K sold.

Pacer Advisors first reported a position in FATE in Q3 2018 and held it in 6 quarters. The position peaked at $137K in Q3 2020. 164 funds tracked by Wall St. Rank hold FATE as of Q3 2024.

  • Pacer Advisors reported no remaining Fate Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 1,426 Fate Therapeutics shares in Q3 2024, an estimated $4.68K.
  • Pacer Advisors first reported a position in Fate Therapeutics in Q3 2018 and held it in 6 quarters.
  • Pacer Advisors's Fate Therapeutics position peaked at $137K in Q3 2020.
  • 164 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.